Aviva’s Revolution Medicines RVMD Stock Holding History

Aviva’s Portfolio RVMD Stock Details RVMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$22.1M	Buy	118,070 +96,610	+450%	+$14.1M	0.03%	401
2026 Q1	$2.09M	Buy	+21,460	New	+$2.17M	﹤0.01%	621

Other funds holding RVMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return

DGM

Darwin Global Management St. Helier, Jersey $3.76B AUM 342.13% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

PBA

Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return

Aviva's RVMD Position: Q2 2026 in Review

Aviva increased its Revolution Medicines (RVMD) stake by 450% in Q2 2026, buying an estimated $14.1M and bringing the position to 118,070 shares worth $22.1M. The position accounts for 0.03% of the portfolio, ranked #401.

Aviva first reported a position in RVMD in Q1 2026 and has held it in 2 quarters since. 690 funds tracked by Wall St. Rank hold RVMD as of Q2 2026.

Aviva held 118,070 shares of Revolution Medicines worth $22.1M as of Q2 2026.
Aviva bought 96,610 Revolution Medicines shares in Q2 2026, an estimated $14.1M.
Revolution Medicines made up 0.03% of Aviva's portfolio in Q2 2026, its #401 holding.
Aviva first reported a position in Revolution Medicines in Q1 2026 and has held it in 2 quarters since.
690 funds tracked by Wall St. Rank held Revolution Medicines as of Q2 2026.

Based on Aviva's 13F filing for Q2 2026, filed 13 Aug 2026.